Association between disease risk and change in body mass index (BMI) or glycated hemoglobin (HbA1c). Source: Diabetes, Obesity, and Metabolism (2024). DOI:10.1111/dom.15896
A research team from the Cleveland Clinic has published the first study to evaluate the independent, real-world impact on clinical outcomes of weight loss and glycemic control in patients with type 2 diabetes treated with antidiabetic medications, specifically GLP-1RAs (a class of drugs that includes Ozempic and Wegovy).
The study found that every 1% reduction in BMI was associated with a 4% reduction in cardiovascular disease risk, regardless of changes in blood glucose levels. Furthermore, blood glucose control was associated with a lower risk of chronic kidney disease, regardless of changes in weight. These results are clinically relevant and highlight the importance of treating patients with type 2 diabetes in terms of both blood glucose control and obesity.
Retrospective findings showed that Published in Diabetes, Obesity, and Metabolismused de-identified data from electronic health records of more than 1,300 patients with type 2 diabetes evaluated at the Cleveland Clinic.
More information:
Anukriti Sharma et al. “Elucidating the role of weight loss and glycemic control in type 2 diabetes patients” Diabetes, Obesity, and Metabolism (2024). DOI: 10.1111/dom.15896
Citation: Study Evaluates Impact of Weight Loss and Blood Glucose Control in Type 2 Diabetes (September 18, 2024) Retrieved September 23, 2024 from https://medicalxpress.com/news/2024-09-impact-weight-loss-blood-sugar.html
This document is subject to copyright. It may not be reproduced without written permission, except for fair dealing for the purposes of personal study or research. The content is provided for informational purposes only.
